At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGTX Cognition Therapeutics, Inc
Early Closed 12-24 13:00:00 EST
0.6480
+0.0340
+5.54%
盘后0.6500
+0.0020+0.31%
16:46 EST
High0.6771
Low0.6002
Vol2.85M
Open0.6144
D1 Closing0.6140
Amplitude12.52%
Mkt Cap26.92M
Tradable Cap22.91M
Total Shares41.55M
T/O1.79M
T/O Rate8.06%
Tradable Shares35.35M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.